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Abstract
Background: a-Dystroglycan is a negatively charged glycoprotein that covers the apical and basolateral membrane of the 
podocyte. Its transmembrane binding to the cytoskeleton is regulated via tyrosine phosphorylation (pY892) of ß- 
dystroglycan. At the basolateral side a-dystroglycan binds the glomerular basement membrane. At the apical membrane, it 
plays a role in the maintenance of the filtration slit. In this study, we evaluated whether ligation of a-dystroglycan with 
specific antibodies or natural ligands induces intracellular signaling, and whether there is an effect on podocyte 
architecture.
Methodology/Principal Findings: Conditionally immortalized podocytes were exposed in vitro to antibodies to a- 
dystroglycan, and to fibronectin, biglycan, laminin and agrin. Intracellular calcium fluxes, phosphorylation of ß-dystroglycan 
and podocyte architecture were studied. Antibodies to a-dystroglycan could specifically induce calcium signaling. 
Fibronectin also induced calcium signaling, and led to dephosphorylation of pY892 in ß-dystroglycan. Ligation of a- 
dystroglycan resulted in an altered actin architecture, a decreased number of podocyte pedicles and a more flattened 
appearance of the podocyte.
Conclusions/Significance: We conclude that ligation of a-dystroglycan on podocytes induces intracellular calcium 
signaling, which leads to an altered cytoskeleton architecture akin to the situation of foot process effacement. In particular 
the ability of fibronectin to induce intracellular signaling events is of interest, since the expression and excretion of this 
protein is upregulated in several proteinuric diseases. Therefore, fibronectin-induced signaling via dystroglycan may be a 
novel mechanism for foot process effacement in proteinuric diseases.
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In troduction
Podocytes are highly specialized glomerular visceral epithelial 
cells that cover the outside of the glomerular basement membrane 
[1]. Podocytes together with the glomerular basement membrane 
and the glomerular endothelium constitute the size and charge 
selective filter of the glomerulus. The podocyte cell body forms 
primary and secondary extensions, which form foot processes that 
interdigitate with those of neighboring podocytes and that are 
attached to each other by the slit diaphragm. In many glomerular 
diseases with proteinuria, podocyte foot processes are effaced, as 
their extensions are lost.
Dystroglycan was identified as a component of the dystrophin 
glycoprotein complex, which is involved in muscular dystrophies 
[2,3]. Thereafter, dystroglycan was described as a component in 
epithelial cells [4,5], and we have shown that dystroglycan is 
expressed by podocytes, both at the basolateral and the apical cell 
membrane [6,7]. The dystroglycan encoding gene DAG1 was first 
cloned and sequenced in 1992. Dystroglycan is post-translationally
cleaved into the extracellular a subunit and the integral membrane 
ß subunit, which non-covalently interact [2]. Dystroglycan provides 
a link between the extracellular matrix like the glomerular basement 
membrane to the actin cytoskeleton of the podocyte. a- Dystrogly- 
can binds to laminin G  modules that are present in laminin and 
agrin, whereas ß-dystroglycan is connected to the actin cytoskeleton 
via dystrophin or its ubiquitous homologue utrophin in the kidney 
[6,8,9]. a-Dystroglycan undergoes massive O-mannosyl glycosila- 
tion with terminal sialic acids, which serve by virtue oftheir negative 
charge as an anti-adhesion layer on the apical podocyte membrane, 
analogous to podocalyxin, a sialic acid-rich glycoprotein that also 
covers the apical cell membrane of the podocyte [7]. The 
glycosilation of a-dystroglycan is necessary for its binding to laminin 
G modules [8]. We have shown previously that deglycosilation of a- 
dystroglycan by reactive oxygen species results in a loss ofbinding to 
agrin and laminin [10].
The small leucine-rich repeat at the C-terminal tail of a- 
dystroglycan has been shown to bind to chondroitin sulfate A and / 
or C on biglycan [11]. Biglycan is a small leucine-rich
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proteoglycan with chondroitin sulfate or dermatan sulfate side 
chains. It has been shown to be predominantly localized in the 
tubular interstitium and intrarenal arteries. Minimal expression of 
biglycan in the mesangial matrix has been described for normal 
human kidney and various glomerular diseases [12-16]. TGF-ß- 
mediated mesangial upregulation of biglycan has been described 
in Thy-1 mediated membranoproliferative glomerulonephritis in 
the rat [17]. TGF-ß induces fibrosis and as a consequence it is 
especially co-localized with collagen type I in fibrosis [13].The 
assembly of chondroitin sulfate side chains decreases after 
exposure to puromycin-aminonucleoside and dexamethasone 
[18,19]. Biglycan is not detectable in the urine of patients with 
glomerular diseases [15].
It was recently shown that the C-terminal domain of muscle a- 
dystroglycan can also bind to fibronectin and fibrinogen [20]. 
Fibronectin is a 500 kDa protein that consists of two similar 
250 kDa subunits linked via a disulfide bond. By post-translational 
processing plasma and tissue isoforms are formed. An increased 
expression of both plasma and tissue fibronectin has been 
documented in various glomerular diseases like diabetic nephrop­
athy, puromycin-aminonucleoside and adriamycin nephrosis [21­
24]. Furthermore, urinary excretion of fibronectin has been shown 
to correlate with proteinuria in IgA-nephropathy, membranous 
glomerulopathy, and diabetic nephropathy and with glomerulo­
sclerosis in lupus nephritis and chronic glomerulonephritis [25-27].
The extracellular N-terminal domain of ß-dystroglycan interacts 
with a-dystroglycan, whereas the intracellular C-terminal domain 
interacts with utrophin [28-30]. In particular, a PPxY motif 
including a tyrosine residue at position 892 in ß-dystroglycan in 
the C-terminal domain is necessary for interaction with WW 
domains in utrophin [28-30]. WW domains are 30-40 amino acid 
motifs containing two conserved tryptophan residues, that bind to 
proline-rich sequences [31]. The interaction of ß-dystroglycan 
with dystrophin/utrophin is stabilized by a helix-turn-helix motif,
i.e. EF hand, close to the PPxY motif in dystrophin/utrophin 
[29,32]. Furthermore, dephosphorylation of Y892 (pY892) in ß- 
dystroglycan enables binding to utrophin/dystrophin [30,33]. 
Phosphorylation of ß-dystroglycan enhances recruitment of SH2/ 
SH3 domain containing proteins like c-Src, Fyn, Csk, NCK, SHC 
and Grb-2, which all are involved in signaling events [34,35]. This 
suggests a role for dystroglycan in signaling.
In this study, we investigated whether ligation of a-dystroglycan 
by monoclonal antibodies against a-dystroglycan and natural
ligands for a-dystroglycan, such as laminin, agrin, biglycan and 
fibronectin, leads to intracellular signaling as assessed by 
measuring calcium fluxes and to changes in the phosphorylation 
status of ß-dystroglycan at position 892 (Y892). In addition, we 
investigated whether a-dystroglycan ligation had an impact on 
actin cytoskeleton architecture and podocyte morphology.
Results
The binding of cultured mouse podocytes to EHS laminin, 
agrin, collagen A and Matrigel coated plates was quantified with 
the hexosaminidase assay. Podocytes were pre-incubated with a- 
dystroglycan specific antibodies, IIH6 or VIA4.1, directed to 
carbohydrate epitopes on a-dystroglycan, prior to seeding on the 
coatings. It is known that monoclonal antibody IIH6 inhibits the 
binding of a-dystroglycan to laminin G modules, whereas 
monoclonal antibody VIA 4.1 does not [4,36]. Indeed, the 
number of podocytes binding to laminin decreased after pre­
incubation with IIH6, but remained unaltered after pre-incubation 
with VIA4.1 (Figure 1A). Pre-incubation with isotype controls for 
either of the a-dystroglycan antibodies (TEPC and MOPC 
respectively) did not affect the binding. As expected, similar 
results were obtained with agrin as coated ligand (data not shown). 
However, the binding of podocytes to collagen A, which is 
comprised of type I collagen that does not contain laminin G 
modules, was unaltered by the addition of either of the two a- 
dystroglycan specific antibodies (Figure 1B). Furthermore, the 
binding of podocytes to Matrigel© which is considered as a 
surrogate basement membrane preparation containing a mixture 
of several extracellular matrix molecules, could not be prevented 
by MoAb IIH6 (data not shown). Therefore, monoclonal antibody 
IIH6 specifically inhibits the binding of mouse podocytes to 
laminin EHS and agrin, indicating an important role for a- 
dystroglycan for the binding of podocytes to laminin G modules 
containing proteins such as laminin and agrin in the glomerular 
basement membrane.
Next, we analyzed whether a-dystroglycan on mouse podocytes 
could mediate outside-in signaling. The ability of monoclonal 
antibodies IIH6 and VIA 4.1 and their respective isotype controls 
to induce calcium fluxes was assessed by the fura 2 method, which 
measures the cytosolic calcium concentration. Both monoclonal 
antibodies could specifically induce calcium signaling after ligation 
of a-dystroglycan, whereas the isotype controls did not (Figure 2A,
0-L------------- -----------------------------------------
Medium IIH6 TEPC 
Collagen A coated plates
Figure 1. Inhibition of podocyte binding to  laminin by anti a-dystroglycan monoclonal antibodies IIH6 and VIA  4.1. Podocytes were 
seeded on laminin (A) or collagen A coatings (B) after pre-incubation with either monoclonal antibody IIH6 using TEPC as an isotype control, or with 
VIA 4.1 using MOPC 21 as an isotype control. Monoclonal antibody IIH6 specifically inhibits podocyte binding to laminin, but not to  collagen A. 
doi:10.1371/journal.pone.0005979.g001
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Figure 2. Calcium fluxes in cultured mouse podocytes after ligation of a-dystroglycan. Mouse podocytes were differentiated on collagen 
A coatings for 2 weeks. Intracellular calcium concentrations were monitored by the fura-2 method, with and w ithout extracellular calcium. Both a- 
dystroglycan specific monoclonal antibodies induced calcium fluxes, most likely from intracellular stores. Isotype controls were negative (A, B). The 
laminin G modules-containing proteins agrin and laminin were unable to induce a calcium influx in podocytes (C, D). From the natural ligands o f a- 
dystroglycan tested, fibronectin induced the most pronounced calcium influx. Note that blocking of potential integrin binding sites with a RGD 
peptide did not influence the fibronectin effect (E). The proteoglycan biglycan induced a modest calcium influx (F). 
doi:10.1371/journal.pone.0005979.g002
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B). The peak of the cytosolic calcium concentration was similar in 
the presence or absence of extracellular calcium, indicating that 
the cytosolic calcium influx was derived from the intracellular 
calcium stores. Although these experiments indicate that ligation 
of a-dystroglycan mobilizes intracellular calcium stores, this 
induction by specific antibodies is however, not a physiological 
event. Therefore, the ability of natural ligands of a-dystroglycan to 
induce a similar rise in cytosolic calcium was investigated. Both 
laminin and agrin, which both can bind to glomerular a- 
dystroglycan [10], were not able to induce a rise in cytosolic 
calcium (Figure 2C, D). Biglycan induced a modest calcium influx 
(Figure 2F). Since the interaction of biglycan with muscle a- 
dystroglycan depends on the chondroitin sulfate side chains of 
biglycan [11], we also tested the effect of adding chondroitin 
sulfate A, B and C, and heparan sulfate. However, both 
chondroitin sulfate preparations as well as heparan sulfate did 
not induce calcium mobilization in the cytosol (data not shown). 
Since fibronectin is a known ligand of muscle a-dystroglycan, and 
a protein which is involved in several glomerular diseases [21-27], 
we evaluated the effect of fibronectin on calcium fluxes. Since we 
could not rule out that RGD motives in fibronectin could induce 
signaling via a3ß[integrin, these RGD fibronectin receptor 
recognition sequences in integrins were blocked by pre-incubation 
with RGD peptide. We included RGD blocking, although 
a3ß1integrins are mainly expressed at the basal and not at the 
apical side of podocytes. Addition of RGD peptide did not result in 
calcium fluxes. Fibronectin, after blocking of a 3ß[integrin with 
RGD peptides, induced the strongest cytosolic calcium influx of all
4 endogenous ligands of a-dystroglycan tested (Figure 2E). This 
finding indicates that fibronectin can induce calcium fluxes in 
podocytes, via other molecules than integrins. To further
ß-DG pY892
A Luminosity 59.6 67.8 31.6 1.04
Figure 3. Fibronectin stimulation of cultured mouse podocytes 
leads to  a decrease of pY892 on ß-dystroglycan. Cultured mouse 
podocytes were incubated for 3 minutes with fibronectin after which a 
decrease o f pY892 was found in Western blot analysis of whole 
podocyte cell lysates (right panel), whereas the total amount o f ß- 
dystroglycan was not affected (left panel). Total ß-dystroglycan was 
probed with NCL-BDG and pY892 was probed with anti-pY892. 
doi:10.1371/journal.pone.0005979.g003
investigate whether the dystroglycan complex is involved in 
fibronectin-induced calcium fluxes in podocytes, its effect on the 
phosphorylation state of Y892 in ß-dystroglycan was investigated. 
It appeared that stimulation of podocytes by fibronectin 
(concomitantly with blocking with RGD peptide) led to a decrease 
in phosphorylation of Y892, while the total amount of ß- 
dystroglycan was unaltered (Figure 3). This latter finding suggests 
that a-dystroglycan is involved in fibronectin-induced calcium 
influxes in podocytes. We have also studied the expression level of 
pY892 in renal sections of control rats and rats with adriamycin 
nephropathy, with normal and effaced podocytes, respectively. We 
applied several antigen retrieval techniques, and an epitope 
preservation approach by inclusion of phosphatase inhibitors. 
However, despite an additional signal amplification, the detectable 
expression levels of pY892 in both control and adriamycin rats 
were extremely low and, therefore, not conclusive (data not 
shown), which seems in contrast to our clear findings with Western 
blot analysis (Figure 3). However, a similar discrepancy between 
immunofluorescence and Western blot analysis has been observed 
on skeletal muscle by others [37]. It has been described that 
differentiation of conditionally immortalized podocytes induces 
process (filopodia) formation [38]. In figure 4 we show the effect of 
the anti-a-dystroglycan monoclonal antibodies and fibronectin on 
the morphology of podocytes and actin cytoskeleton. All ligands 
induced a retraction of filopodia and a reorganization of the 
cytoskeleton. Statistical analysis of these effects revealed a 
significant effect for the anti-a-dystroglycan monoclonals IIH6 
and VIA 4.1, but only a trend for fibronectin (Table 1). However, 
in several fibronectin-stimulated cells retraction of filopodia was 
clearly visible as shown in the lower panels of figure 4. This 
reorganization of the actin cytoskeleton may be a situation 
reminiscent of foot process effacement. These data suggest that 
fibronectin-induced signaling events, mediated by the dystroglycan 
complex leads to an altered podocyte architecture.
Discussion
a-Dystroglycan is a negatively charged glycoprotein, which 
covers the apical and basolateral membrane of the podocyte. At 
the basolateral side a-dystroglycan binds laminin G modules in 
agrin and laminin. The a3ß1integrin is also expressed at the 
basolateral side of podocytes, where it extracellulary binds to 
laminin, fibronectin and collagen. In this study we investigated the 
importance of a-dystroglycan for the binding of podocytes to 
laminin, agrin and several other extracellular matrix molecules 
with a new binding assay. Binding of monoclonal antibody IIH6 
but not monoclonal antibody VIA4.1 inhibited the binding of 
podocytes to laminin and agrin. Our findings with podocytes are 
similar to the data for the binding of Schwannoma cells to laminin 
as previously described [36]. This is also underlined by the 
observation that monoclonal antibody VIA 4.1 did not inhibit the 
binding/growth of podocytes to collagen nor to laminin and agrin, 
since the carbohydrates recognized by VIA4.1 are not involved in 
the binding to laminin G moieties [4,36]. However, no 
impairment of binding of podocytes to collagen type I coated 
plates was observed after incubation with monoclonal antibody 
IIH6. Furthermore, binding ofpodocytes to Matrigel-coated plates 
also could not be inhibited by IIH6, which not unexpectedly 
suggests that podocytes also can bind to additional molecules 
without laminin G modules. As over 50% of the binding of 
podocytes to laminin was lost by the addition of monoclonal 
antibody IIH6, it can be concluded that for binding to laminin a- 
dystroglycan on podocytes is of equal or even greater importance 
than a 3ß[integrins. Therefore, our in vitro findings suggest that a-
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Control Stimulation
Figure 4. Ligation of a-dystroglycan results in a loss of pedicles in cultured mouse podocytes. Differentiated podocytes on collagen 
coatings were incubated with either monoclonal antibodies IIH6 or VIA 4.1, their respective isotype controls (TEPC or MOPC) or fibronectin. The 
podocyte pedicles (arrow) are probed with antibodies against Mena (green, which also localizes along stress fibers and in focal contacts at the tips of 
stress fibers [58,65]). The pedicles were lost after 6 hours of incubation with the antibodies. As these pedicles may be the in vitro manifestation o f foot 
processes, their retraction may imply foot process effacement. Percentage of podocytes with smooth surfaces were counted, which yielded for IIH6 
60% versus TEPC 30% (x2 = 20.8, p<0.001), for VIA4.1 51% versus MOPC 28% (x2 = 9.01, p<0.01) and fibronectin 38% versus control 30% (x2= 1.3, 
p = 0.25). (Red = phalloidin (actin); blue=DAPI (DNA)). 
doi:10.1371/journal.pone.0005979.g004
dystroglycan represents an important mechanism for podocytes to 
anchor to the glomerular basement membrane.
At the apical domain of the podocyte the assumed function of 
the dystroglycan complex is maintenance of the filtration slit by its
negative charge [7]. In this study, we investigated whether 
dystroglycan plays a role in outside-inside signaling events. Indeed, 
we observed a specific cytosolic calcium influx in cultured mouse 
podocytes after ligation of a-dystroglycan by two different anti a-
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Table 1. Percentages of podocytes with smooth, intermediate or filopodia rich surfaces after in vitro ligation with a-dystroglycan 
specific antibodies, fibronectin and their respective controls.
IIH6** TEPC 183** VIA4.1 *** ***MOPC21 FN+ FN-
Filopodia rich* 12 25 17 28 18 23
Intermediate* 28 45 32 44 44 46
Smooth* 60 30 51 28 38 30
*Smooth 0-0.2 fìlopodia/5 mm, intermediate 0.2-1 filopodia/5 mm or filopodia rich $1 filopodia/5 mm cell border. 
^Significantly different when comparing frequencies in both columns; IIH6 vs. TEPC183 x 2 = 20.8, p<0.001. 
***VIA4.1 vs. MOPC21 x 2 = 9.01, p<0.01 Fibronectin+(FN+) vs. control (FN-) x2 = 1.3, p = 0.25. 
doi:10.1371/journal.pone.0005979.t001
dystroglycan antibodies. This rise in the cytosolic calcium 
concentration comes mainly from the intracellular calcium stores, 
since it was not dependent on the extracellular calcium 
concentration. This increase in cytosolic calcium is presumably 
mediated via inositol-1,4,5 tri-phosphate in the endoplasmatic 
reticulum [39].
Since induction of calcium fluxes by these anti a-dystroglycan 
specific antibodies is not a physiological event, we were interested 
in the effects of natural ligands of dystroglycan like, laminin, agrin, 
biglycan and fibronectin. From these ligands fibronectin induced 
the most pronounced signal, biglycan induced only a weak 
increase in cytosolic calcium, while agrin and laminin were not 
able to induce such an effect. This difference may be related to the 
fact that the function of a-dystroglycan on the basal side of the 
podocyte is different from the function at the apical side. 
Furthermore, clustering of a-dystroglycan can be induced by the 
antibodies, fibronectin and biglycan, as they may all serve as 
bivalent ligands [20]. In contrast, agrin and laminin probably 
serve as monovalent ligands. Tandem LG modules are necessary 
for a-dystroglycan binding. Since agrin contains only 3 LG 
modules, only one tandem is available [40]. Laminin possesses 5 
LG modules which enable the formation of maximally two LG 
tandems. However, their spatial relationship within the molecule 
may be to close to cross link a-dystroglycan [41], for review see 
[42]. The fibronectin induced rise in cytosolic calcium can in 
theory be mediated via many complexes. The integrin a 3ß1 can 
bind fibronectin via a RGD module, and is intracellulary linked to 
integrin linked kinase (ILK) which is involved in regulation of the 
actin cytoskeleton, morphology and cell survival via signaling 
events [43,44]. However, the involvement of integrins in the 
fibronectin-induced rise in cytosolic calcium was excluded by 
blocking with an RGD peptide. Furthermore, probing of 
podocytes with fibronectin induced a dephosphorylation of ß- 
dystroglycan, which makes a role for a-dystroglycan in fibronectin 
induced signaling likely. Immunoprecipitation studies in our 
laboratory have indeed showed that glomerular a-dystroglycan 
can bind fibronectin (data not shown), confirming previously 
published observations [20]. Intact fibronectin chains (~250 kDa) 
can only pass the glomerular basement membrane if proteinuria is 
present, and indeed urinary fibronectin correlates with proteinuria 
[25-27]. Importantly, tissue fibronectin is upregulated during 
several glomerular diseases [21-24].
The unraveling of the downstream signaling pathways after 
dystroglycan ligation in podocytes remains challenging. The PPxY 
domain of ß-dystroglycan can recruit SH2/SH3 domain-contain­
ing proteins like c-Src, Fyn, Csk, NCK, SHC and Grb-2. These 
interactions are enhanced by phosphorylation of pY892 [34]. 
From these, c-Src has been shown to be able to phosphorylate 
Y892 in c-Src overexpressing COS7 cells [37]. Also the expression 
ofpY892 ß-dystroglycan increases in COS7 cells when cultured on
coatings of laminin, agrin or fibronectin [37]. Caveolin 1 and 3 co­
express with ß-dystroglycan in lipid raft domains, and bind when 
Y892 is phosphorylated. Caveolin 3 has been shown to inhibit the 
c-Src induced phosphorylation of Y892. [45]. Furthermore, the 
proline-rich SH3 region of Grb-2 binds at the C terminal side of ß- 
dystroglycan [35]. p125FAK has been shown to be linked to Grb-2, 
but not directly to ß-dystroglycan [46]. Taken together, the 
dynamic role of ß-dystroglycan in signaling seems to provide 
docking sites for multiple kinases when phosphorylated, or to 
provide a stable anchorage to the actin cytoskeleton when 
dephosphorylated. A similar phenomenon was illustrated by a 
study in which the Src family kinases were shown to be important 
for the stability of dystroglycan containing clusters induced by 
agrin [47]. ß-dystroglycan also is able to bind ezrin, which also 
affects its interaction with the actin cytoskeleton [48]. Dystrogly­
can suppresses laminin 1 and -10/11 induced ERK activation via 
a6ßj integrin and direct linking of ß-dystroglycan to the ERK- 
MAP kinase pathway has also been described in COS 7 cells 
[49,50]. Recently, genetic interaction screens on presumed 
modifier genes for dystroglycan and dystrophin in many 
drosophila melanogaster mutants, added even more putative 
signaling pathways, like the Notch, TGF-ß, EGFR, Semaphorin- 
Plexin, Frazzled-Netrin and Slit-Robo pathways [51].
Unfortunately, in co-immunoprecipitation experiments we 
could not find any binding of ß-dystroglycan to Src, Grb2, 
p125FAK and ezrin in rat kidney lysates (data not shown). So the 
signaling pathways linked to ß-dystroglycan in podocytes remains 
subject for further investigation.
Alterations in podocyte shape and function are calcium 
dependent. This has been shown in the calcium switch model in 
podocytes, in which 90 minutes removal of extracellular calcium 
results in an increased paracellular flux of dextrans [52]. 
Mutations in the canonical transient receptor potential 6 (TRPC6) 
result in an increased amplitude of the calcium current from the 
extracellular calcium stores, and eventually leads to a form of 
autosomal dominant focal segmental glomerulosclerosis [53,54]. 
However, the calcium flux induced via a-dystroglycan is derived 
from the intracellular calcium stores, which suggests that TRPC6 
is not involved in these events. Furthermore, podocyte shape 
alterations can be induced by sialidase or puromycin aminonu- 
cleoside in rats; dephosphorylation of ezrin linked to podocalyxin 
via NHERF2 results in dissociation from the actin cytoskeleton 
and concomitant foot process effacement [55]. The involvement of 
ß-dystroglycan in fibronectin-induced signaling is shown by the 
decrease in phosphorylation of Y892, which however enhances 
binding of the dystroglycan complex to the actin cytoskeleton via 
utrophin. The impact of this enhanced binding to actin was 
visualized by changes in podocyte morphology. We observed a 
reorganization of the actin cytoskeleton after ligation of a- 
dystroglycan, with monoclonal antibodies to a-dystroglycan and
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in a subset of podocytes with fibronectin. This was accompanied 
by a retraction of branches of cultured mouse podocytes. Similar 
observations have been made by Rüdiger et al. after exposure of 
mouse podocytes to protamin sulfate, which resulted in instant 
calcium influxes, and podocyte foot process retraction after 2 hrs 
[56]. Protamin sulfate inhibits the binding of a-dystroglycan to 
laminin and can also bind a-dystroglycan, in vivo injection results in 
immediate foot process effacement and endocytosis of a- 
dystroglycan [57]. Thus, the in vitro retraction of foot processes 
may reflect in vivo podocyte foot process effacement.
In summary, the binding of fibronectin to apical free accessible 
a-dystroglycan leads to signaling events in the podocytes, as 
indicated by a rise in cytosolic calcium and a dephosphorylation of 
ß-dystroglycan, enabling utrophin and the actin cytoskeleton to 
bind and retract the podocyte foot process. This may represent a 
novel mechanism of podocyte foot process effacement in 
proteinuric disease.
M ethods
Cell culture
Conditionally immortalized mouse podocytes (MPC-5, gener­
ously provided by Peter Mundel, Division of Nephrology, Albert 
Einstein College of Medicine, Bronx, NY, USA) were cultured 
essentially as described before [7,38]. MPC-5 express a-dystrogly­
can at their apical and basal cell membrane [7]. Passages 12-17 
were used in these experiments. Indirect immunofluorescence was 
performed as described previously [7].
Anti-Mena antibody (Becton Dickinson, Transduction Labora­
tories, San Jose, CA, USA) dilution 1:40 and goat anti-mouse IgA 
FITC (Southern Biotech, Birmingham, Alabama, USA) dilution 
1:50 were used to probe the filopodia. [58]. Phalloidin-TRITC 
(Molecular Probes, Leiden, The Netherlands) dilution 1:150, and 
DAPI (Molecular Probes) dilution 3*10_5 was used to visualize the 
actin cytoskeleton and DNA, respectively. Sections were investi­
gated by a Leica DM 4000 B microscope (Leica Microsystems, 
Rijswijk, the Netherlands). Filopodia count on the cell border was 
studied as follows: The number of filopodia of 2 mm or longer was 
counted per 5 mm cell border. Cells were divided into 3 categories: 
smooth 0-0.2 filopodia/5 mm, intermediate 0.2-1 filopodia/5 mm 
or filopodia rich $1 filopodia/5 mm cell border. The frequencies 
in the groups were compared using x2.
For the investigation of binding, propagated podocytes were 
seeded overnight on laminin EHS (Campro Scientific; Veenen­
daal, The Netherlands) or collagen A (Biochrom, Berlin, 
Germany) coated 96 microwell plates (Costar, Corning Life 
Sciences, Corning, NY) using 3000 podocytes/well with the 
addition of 1 mM a-dystroglycan specific monoclonal antibodies, 
IIH6 or VIA4.1 [59], or their respective isotype controls, MOPC 
21 or TEPC 183 (Sigma, St Louis, MO). Notably, the 
glycoepitopes on glomerular a-dystroglycan are recognized by 
the antibodies IIH6 and VIA4.1 and expressed by cultured mouse 
podocytes [7,60]. Podocytes were inversely centrifuged at 200 g 
for 1 minute and carefully rinsed three times with phosphate 
buffered saline (PBS, Merck, Darmstadt, Germany).
To evaluate the number of podocytes a hexosaminidase essay 
was performed in which the amount of the house keeping enzyme 
hexosaminidase is quantified by measuring the digestion of p- 
nitrophenyl-N-acetyl-ß-D-glucosamidine [61]. In short: podocytes 
were incubated overnight at 37°C with 100 ml 50 mM citrate 
(Merck), 3.75 mM p-nitrophenyl-N-acetyl-ß-D-glucosamidine
(Sigma) and 0.25% Triton x100 (Sigma). Thereafter, the reaction 
was blocked with a solution containing 50 mM glycine (Sigma) 
and 5 mM EDTA, pH 10.4, 150 ml/well. Optical density was 
measured at 405 nm. Two-tailed Student-t test was performed and 
P#0.05 was considered significant.
Measurement of calcium fluxes
Propagated podocytes were seeded on collagen A coated glass 
cover slips and differentiated for 3 weeks. Subsequently, cells were 
loaded with 5 mM fura-2-AM (Molecular Probes) and 0.025% 
pluronic-F127 (Molecular Probes), added to the medium of 
differentiated podocytes for 20 minutes at 37°C. Subsequently, 
they were washed and mounted in a bath-chamber in 137 mM 
NaCl, 3.6 mM KCl, 1 mM CaCl2 , 1 mM MgCl2 , 5,5 mM D- 
glucose and 10 mM Hepes-Tris buffer pH 7.4 (Sigma) at 37°C 
and placed under an inverted microscope (Nikon) attached to a 
videorate confocal microscope (Noran Instruments, Middleton, 
WI). Calcium-free measurements were performed in the same 
buffer without calcium and with 2 mM ethylene glycol tetra-acetic 
acid (EGTA, Sigma) added. The podocytes were excited 15 times/ 
min at 340 and 380 nm, with an exposure time of 100 ms and 
single cell emission at 492 nm was monitored as a measure of the 
cytosolic free calcium concentration. Dynamic video imaging was 
carried out using the MagiCal hardware and Tardis software [62]. 
The effects of the addition of 1 mM biglycan (Sigma), 1 mM 
laminin, 1 mM IIH6, 1 mM VIA4.1, 1 mM MOPC 21, 1 mM 
TEPC 183 (Sigma), 1 mM heparan sulfate (Seikagaku), a mixture 
of 2 mg/ml chondroitin sulfate A, 1 mM B and C (Sigma), or 
0.025 mg/ml rat fibronectin (250 kDa chains, Sigma) on calcium 
fluxes were evaluated. Only for the measurement of the effect of 
fibronectin on calcium fluxes, podocytes were prior to the addition 
of fibronectin maintained in serum-free medium for 24 hrs. 
Possible fibronectin binding sites on integrins were blocked with 
GRGDS peptide (160 mM, Sigma).
Western blot analysis
Western blot analysis was performed according to the methods 
of Laemmli and as described recently [10,63]. Whole podocyte cell 
lysates were blotted onto nitrocellulose and blocked with 5% non­
fat dry milk (Biorad, Veenendaal, the Netherlands) in PBS. 
Phosphatase inhibitors, 10 mM NaF (Sigma) and 1 mM sodium 
orthovanadate (Sigma), were added to the buffers used during the 
whole procedure to prevent dephosphorylation [64]. Anti-pY892 
(1:50 BD Biosciences, San Jose, USA) and NCL-BDG (1:10 
Novocastra, Newcastle upon Tyne, United Kingdom) were used as 
primary antibodies. Peroxidase labeled goat anti mouse 
IgGH+L1:5000, was used as secondary antibody.
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